Priyadharsini Nagarajan

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

31h-index3.8kcitations296works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nonmelanoma Skin Cancer Studies(89), Cutaneous Melanoma Detection and Management(78), Polyomavirus and related diseases(42), Cutaneous lymphoproliferative disorders research(41), Ear and Head Tumors(40)

Publications296 total

Abstract A036: Spatial multi-omics identifies a tumor microenvironment signature predictive of immunotherapy response in mucosal melanomas
Cancer Immunology Research·2026
CD274 Alterations and PD-L1 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Patients With Melanoma: Relationships to Histopathologic Features and Outcomes
Archives of Pathology & Laboratory Medicine·2026Open Access
NPM1-Mutated Myeloid Sarcoma/Leukemia Cutis Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm and Heralding Bone Marrow Acute Myeloid Leukemia
American Journal of Dermatopathology·2025
Pediatric Primary Cutaneous <scp>CD8</scp> + Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course
Journal of Cutaneous Pathology·2025Open Access
Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma
npj Precision Oncology·2025Open Access
Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma
Head & Neck·2025Open Access
Blue‐Gray Papules on the Chest and Face
JEADV Clinical Practice·2025Open Access
1659P Updated pathologic responses from a pilot phase II trial of neoadjuvant immunotherapy for stage II-IV resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
Annals of Oncology·2025
1701eTiP NRG-HN014 (C-PRE): A randomized phase III study of neoadjuvant immunotherapy with response-adapted treatment versus standard-of-care treatment for patients with resectable stage III-IV (M0) cutaneous squamous cell carcinoma (cSCC)
Annals of Oncology·2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
Nature·2025· 22 citedOpen Access
Response-Adapted Oncologic Surgery in Cutaneous Squamous Cell Carcinoma: A Paradigm Shift Following Neoadjuvant Immunotherapy
Annals of Surgical Oncology·2025· 4 cited
A Case of a Fumarate Hydratase Deficient Astrocytoma in Association With a Germline Fumarate Hydratase Mutation With Review of the Literature
The American Journal of Surgical Pathology·2025· 3 cited
Corrigendum to “Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features” [Modern Pathology 33 (2020) 496–513]
Modern Pathology·2025
INSM1: A highly sensitive marker for primary and metastatic Merkel cell carcinoma, superior to SOX11, pancytokeratin, and CK20
Human Pathology·2025· 2 cited
TROP2 is highly expressed in cutaneous squamous cell carcinomas and a subset of adnexal carcinomas: A potential therapeutic target with TROP2-directed antibody drug conjugates
Human Pathology·2025· 1 cited
Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune checkpoint inhibitor (ICI) treatment.
Journal of Clinical Oncology·2025
NSD3::FGFR1: A Novel Gene Fusion First to Be Described in Merkel Cell Carcinoma
American Journal of Dermatopathology·2025· 2 cited
Genomic and Transcriptomic Profiling of Digital Papillary Adenocarcinomas Reveals Alterations in Matrix Remodeling and Metabolic Genes
Journal of Cutaneous Pathology·2025· 2 cited
1256 Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma response and resistance to immune checkpoint inhibitor treatment
Regular and Young Investigator Award Abstracts·2024Open Access
Stem cell activity-coupled suppression of endogenous retrovirus governs adult tissue regeneration
Cell·2024· 12 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Michael T. Tetzlaff(21), Víctor G. Prieto(21), Jonathan L. Curry(20), Carlos A. Torres‐Cabala(20), Phyu P. Aung(20), Doina Ivan(12), Jennifer A. Wargo(8), Bita Esmaeli(8), Adi Diab(7), Renata Ferrarotto(7), Moran Amit(6), Bonnie S. Glisson(6), Neil D. Gross(6), Michael K. Wong(5), Jing Ning(5), Adel K. El‐Naggar(4), David I. Rosenthal(4), Randal S. Weber(4), Jeffrey N. Myers(4), Michael R. Migden(4)